
Does AI Aid Rare Bone Fracture Detection in Children?
In patients with osteogenesis imperfecta, artificial intelligence (AI) assistance improved the fracture detection accuracy of radiologists from 83.4% to 90.7%. However, radiologists performed better than AI when their standalone performance was considered.
METHODOLOGY:
In this study, researchers analysed 336 appendicular and pelvic radiographs of 48 children (mean age, 12 years) with genetically confirmed osteogenesis imperfecta.
The ground truth was determined by a consensus opinion of two consultant paediatric radiologists who labelled acute and healing fractures with bounding boxes.
Seven radiologists independently evaluated anonymised images in two rounds — the first round without AI and the second round with AI assistance. The AI tool provided bounding boxes for suspected fractures but did not distinguish acute from healing fractures.
After both rounds were completed, the results from radiologists without AI assistance, radiologists with AI assistance, and the AI alone were compared against the ground truth by calculating the intersection between the bounding boxes.
TAKEAWAY:
AI demonstrated a per-examination accuracy of 74.8% (95% CI, 65.4%-82.7%), compared with the average radiologist performance of 83.4% (95% CI, 75.2%-89.8%).
Radiologists using AI assistance improved their average accuracy per examination to 90.7% (95% CI, 83.5%-95.4%).
AI support increased average radiologist per-image accuracy by 7.0% (from 84.6% to 91.6%) and per-fracture accuracy by 3.7% (from 76.3% to 80.0%).
Per fracture, AI assistance lowered true and false positives while raising true and false negatives, boosting the accuracy by 3.7%, specificity by 10.0%, and positive predictive value by 7.2%.
On average, radiologists changed their per-fracture decisions in 72 instances; 69% of those changes matched the AI's suggestion, and 64% improved accuracy.
IN PRACTICE:
"In conclusion, the results of this study suggest that AI assistance improves radiologists' performance in diagnosing fractures in children with OI [osteogenesis imperfecta], even if it is not specifically trained for this population," the authors of the study wrote. "Nevertheless, compared to radiologists, the standalone AI performance was worse, thus highlighting potential dangers of implementing the AI tool in an autonomous manner," they added.
SOURCE:
This study was led by Cato Pauling, University College London, London, England. It was published online on July 07, 2025, in European Radiology.
LIMITATIONS:
Researchers included repeat examinations from some patients over the study period, which may have introduced bias due to similarities in appearances. This study used only one commercially available AI model, despite multiple products being available in the market. Additionally, the lack of a control group of patients without bone fragility disorder made it challenging to objectively evaluate whether the AI tool performed less accurately in children with osteogenesis imperfecta.
DISCLOSURES:
This study received funding support from the National Institute for Health and Care Research. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
11 hours ago
- Associated Press
Raman Bhaumik and TSP Launch New Provider Portal to Streamline Compounded Prescription Ordering and Compliance
PLANO, Texas--(BUSINESS WIRE)--Jul 30, 2025-- Texas Star Pharmacy (TSP), in partnership with SiCompounding, has announced the official launch of the Texas Star Provider Portal, a next-generation digital platform developed under the leadership of Raman Bhaumik. Purpose-built for physicians, clinics, IV infusion centers, and internal pharmacy teams, the cutting-edge portal is designed to simplify the ordering, tracking, and compliance processes associated with compounded prescriptions. The newly released Provider Portal significantly enhances the operational efficiency of prescription fulfillment by replacing outdated manual workflows with a secure, technology-driven solution. Core features include a HIPAA-compliant prescription submission system, real-time order tracking, integrated compliance checkpoints, secure messaging for prescription clarifications, and streamlined payment processing. 'We recognized the urgent need to eliminate inefficiencies and compliance risks in compounded medication ordering,' said Raman Bhaumik, Chief People Officer. 'The Provider Portal is a direct response to those needs. It's designed to give providers the transparency, speed, and accuracy they deserve while safeguarding patient safety and meeting all state and federal regulations.' The benefits have proved immediately evident for healthcare providers. By reducing the administrative burden and eliminating common prescription errors, the portal allows clinicians to focus more on patient care. The platform also enhances communication between providers and pharmacists, reducing time-consuming back-and-forth phone calls and ensuring all parties are aligned on medication protocols and delivery timelines. Built with scalability and adaptability in mind, the portal leverages real-time dashboards and integrates with leading pharmacy management systems. It is accessible via desktop and mobile platforms, offering 24/7 availability for busy healthcare professionals. Additionally, continuous improvements are underway, with beta testing currently live and operational at Texas Star Pharmacy locations. With this launch, Texas Star Pharmacy reaffirms its commitment to innovation, patient-centric care, and healthcare provider support. This initiative reflects the pharmacy's broader mission to use technology as a bridge between modern medical practice and precision compounding. Raman Bhaumik is a respected healthcare executive and visionary leader with extensive expertise in pharmacy management and operational efficiency. A licensed pharmacist across multiple states, she has completed advanced leadership training and brings a global approach to strategic planning. As the owner of Texas Star Pharmacy, Raman's dedication to process improvement has driven her business to success. She is passionate about mentoring future healthcare professionals and actively supports the next generation of more information about Texas Star Pharmacy, visit To learn more about SiCompounding, visit View source version on CONTACT: Media Contact: Autumn Allen Phone: 469-476-1002 Email:[email protected] KEYWORD: TEXAS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH DATA MANAGEMENT PHARMACEUTICAL TECHNOLOGY HEALTH TECHNOLOGY SOURCE: Texas Star Pharmacy Copyright Business Wire 2025. PUB: 07/30/2025 02:53 PM/DISC: 07/30/2025 02:53 PM

Associated Press
20 hours ago
- Associated Press
Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone
'Driving the Globalization of Clinical Trials in the Guangdong-Hong Kong-Macao Greater Bay Area, Implementing the First Key Cross-Border Multi-Center Clinical Trial Project' HONG KONG SAR - Media OutReach Newswire - 30 July 2025 - The Greater Bay Area International Clinical Trial Institute of Hong Kong ('GBAICTI'), the Greater Bay Area International Clinical Trials Center of Shenzhen ('BAY TRIAL'), Immuno Cure BioTech ('Immuno Cure') in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding ('MOU') in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area ('GBA'), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. From left to right: Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI; Dr. Xia JIN, Chief Executive Officer of Immuno Cure; Ms. TANG Hongmei, Executive Director of BAY TRIAL This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen. GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform ('Platform') by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong. Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: 'The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.' Dr. LI Yichong, Director of BAY TRIAL, said: 'This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area's pharmaceutical and medical device industry.' Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy ('ART') can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host's immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure's ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART. Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People's Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People's Hospital, Tianjin Second People's Hospital, The Sixth People's Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center. Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: 'We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure's therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.' GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national 'Healthy China' strategic goals. Hashtag: #ImmunoCure #醫克生物 #医克生物 The issuer is solely responsible for the content of this announcement. About GBAICTI The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission is to coordinate public and private medical resources in Hong Kong, providing a one-stop support platform for research institutions. This aims to promote process optimization, talent training, and collaboration within the Greater Bay Area, accelerating the research and development of drugs and medical devices, allowing research outcomes to benefit patients more quickly. By closely collaborating with the Greater Bay Area International Clinical Trials Center, it leverages the unique advantages of 'one institute, one center' to jointly coordinate cross-border, multi-center clinical trials that meet international standards. To learn more about GBAICTI, please visit: About BAY TRIAL The Greater Bay Area International Clinical Trials Center (BAY TRIAL) is a key initiative in implementing the 'Notice of the State Council on Issuing the Development Plan for the Shenzhen Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone' (State Council [2023] No. 12). It serves as strong support for Shenzhen's development as an international science and technology innovation centre and for promoting the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Located in the Hetao Shenzhen-Hong Kong Cooperation Zone, BAY TRIAL leverages the zone's unique geographical and policy advantages to integrate clinical trial innovation resources across the GBA, deepen Shenzhen-Hong Kong science and technology collaboration, and establish a one-stop clinical trial platform. This platform provides top-tier clinical trial technical support, operational management, and registration services for domestic and international pharmaceutical and medical device R&D institutions. Additionally, BAY TRIAL will act as a 'testing ground' for clinical trial regulation reforms and a 'catalyst' for technological innovation, facilitating the alignment of clinical trial regulations and standards with international benchmarks, promoting the development and application of cutting-edge trial technologies, building a collaborative medical technology innovation network in the GBA, and enhancing the region's competitiveness in the pharmaceutical and medical device industry. To learn more about BAY TRIAL, please visit: About Immuno Cure Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms. To learn more about Immuno Cure, please visit:
Yahoo
21 hours ago
- Yahoo
Emerging Markets Drive Growth with Government and Private Investments, Infrastructure Development, and Technological Advancements
The medical displays market is projected to grow from USD 2.64 billion in 2025 to USD 3.45 billion by 2030, at a CAGR of 5.5%. Key drivers include advancements in imaging technologies, demand for precise diagnostics, and increased chronic disease prevalence. Emerging economies, digital healthcare adoption, and telemedicine are also fueling growth. The Asia Pacific is set to lead due to healthcare investments and aging populations. Challenges include high costs and limited access in underdeveloped areas. Leading companies like Barco NV and Sony Electronics are analyzed, along with trends in technology and regional market dynamics. The report offers insights for strategic market positioning and future growth opportunities. Global Medical Display Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Medical Display Market by Technology (LED-Backlit LCD Display), Panel Size (Under 22.9 Inch Panels), Resolution (4.1-8 MP Resolution Display), Display Color (Color & Monochrome Display), Application (Diagnostics Applications, Dentistry) - Global Forecast to 2030" report has been added to medical displays market is projected to reach USD 3.45 billion by 2030 from USD 2.64 billion in 2025, at a CAGR of 5.5% during the forecast period. The report is designed to help both market leaders and new entrants by providing data on revenue estimates for the overall medical displays market and its subsegments. It will also assist stakeholders in understanding the competitive landscape, allowing them to gain valuable insights for positioning their businesses and developing effective go-to-market strategies. Additionally, the report offers stakeholders a clear understanding of market trends and provides information on key drivers, challenges, obstacles, and opportunities within the market. The medical displays market is influenced by several key factors, including advancements in imaging technologies, an increasing demand for accurate diagnostics, and the rising prevalence of chronic diseases. Additionally, growing healthcare investments, particularly in emerging economies, and the shift toward digital healthcare systems are driving market growth. Regulatory standards for image quality, the need for high-resolution displays in radiology and surgery, and the expansion of telemedicine also affect demand. However, high costs and limited access in underdeveloped regions may hinder market displays with a resolution of 4.1 to 8 megapixels hold the largest market share due to their ability to provide high image clarity, which is crucial for accurate diagnosis, particularly in radiology and surgical applications. These displays allow for detailed visualization of complex anatomical structures, thereby enhancing diagnostic confidence. Their combination of performance and cost-effectiveness makes them widely preferred in hospitals and diagnostic display color, color displays dominate the medical displays market because they offer detailed, multidimensional imaging that is crucial for accurate diagnosis and surgical guidance. They are compatible with advanced imaging techniques such as MRI and CT, where color differentiation improves interpretation. Their versatility and common use across various specialties make them the preferred choice in modern healthcare Asia Pacific region is forecasted to experience the highest growth rate in the medical displays market. This growth is driven by several factors, including increased investments in healthcare, the rapid adoption of advanced imaging technologies, and the expansion of healthcare infrastructure. Additionally, rising awareness of early disease diagnosis, a growing geriatric population, and the increasing prevalence of chronic diseases are fueling demand. Furthermore, improving government initiatives and favorable policies, along with the presence of emerging economies such as China and India, are contributing to the region's accelerated market expansion during the forecast period. Prominent players in the medical displays market are Barco NV (Belgium), EIZO (Japan), Sony Electronics Inc. (Japan), LG Electronics (South Korea), Novanta (US), FSN Medical Technologies (South Korea), Advantech (Taiwan), Quest International (US), STERIS (UK), Jusha Medical (China), Siemens Healthineers AG (Germany), Double Black Imaging (US), HP Development Co. Ltd. (US), Stryker (US), and COJE Displays (South Korea).Insights Provided: Key Drivers: Adoption of hybrid operating rooms, short medical display replacement cycles, preference for minimally invasive treatments, and increased diagnostic imaging centers. Restraints: Market saturation in developed nations, refurbished medical display adoption, and US medical device excise tax. Opportunities: Investments in emerging economies' healthcare sectors and enhanced healthcare infrastructure. Challenges: Consumer-grade display adoption, costs of new display technologies, and hospital budget cuts. Product Enhancement/Innovation: Detailed information on product launches and upcoming trends in the global market. Market Development: Insights into profitable rising markets by technology, panel size, resolution, display color, and application. Market Diversification: Information on new products, service expansions, and investments. Competitive Assessment: Evaluation of market shares, growth plans, offerings, and capacities of major competitors. Key Attributes: Report Attribute Details No. of Pages 310 Forecast Period 2025 - 2030 Estimated Market Value in 2025 2.64 Billion Forecasted Market Value by 2030 3.45 Billion Compound Annual Growth Rate 5.5% Regions Covered Global Market Dynamics Drivers Growing Adoption of Hybrid Operating Rooms Short Replacement Cycles of Medical Displays Increasing Preference for Minimally Invasive Treatments Rising Number of Diagnostic Imaging Centers Challenges Market Saturation in Developed Countries Increasing Adoption of Refurbished Medical Displays Excise Tax on Medical Devices in US Opportunities Increasing Investments from Government Bodies and Private Players in Emerging Economies Development of Healthcare Infrastructure in Emerging Markets Technological Advancements Industry Trends Growing Consolidation in Medical Displays Market Shift Toward High-Resolution & Multimodality Imaging (4K, 8K, and HDR) Case Studies Case Study 1: Revolutionizing Digital Pathology Imaging Case Study 2: 3D Visualization for Complex Medical Cases Case Study 3: Enhancing Diagnostic Accuracy in Radiology Companies Featured Barco Nv Eizo Inc. Sony Electronics Inc. Novanta Inc. Shenzhen Beacon Display Technology Co. Ltd. Lg Electronics Fsn Medical Technologies Advantech Co. Ltd. Quest International Steris Jusha Medical Siemens Healthineers Double Black Imaging Hp Development Company, L.P. Stryker Coje Displays Axiomtek Benq America Corporation Jvckenwood Usa Corporation American Portwell Technology, Inc. Auo Display Plus Canvys - Visual Technology Solutions Qingdao Hisense Medical Equipment Co. Ltd. Kortek Corporation D&T Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Global Medical Display Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data